



European Monitoring Centre
for Drugs and Drug Addiction

JOINT REPORTS

ISSN 1977-7868

4F-iBF

EMCDDA–Europol Joint Report on a new psychoactive substance: *N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyrylfentanyl; 4F-iBF)

In accordance with Article 5 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances

About this series

EMCDDA–Europol Joint Report publications examine the detailed information provided by the EU Member States on individual new psychoactive substances. Information is collected from the Reitox network, the Europol National Units and the national competent authorities of the European Medicines Agency.

Each Joint Report serves as the basis upon which the decision to conduct a risk assessment of the new psychoactive substance is taken. It is part of the three-step procedure involving information exchange, risk assessment and decision-making in the framework of Council Decision 2005/387/JHA.

Contents

3	1. Introduction
3	2. Information collection process
4	3. Information required by Article 5.2 of the Council Decision
4	3.1 Chemical and physical description, including the names under which the new psychoactive substance is known (Article 5.2(a) of the Council Decision)
6	3.2 Information on the frequency, circumstances and/or quantities in which a new psychoactive substance is encountered, and information on the means and methods of manufacture of the new psychoactive substance (Article 5.2(b) of the Council Decision)
6	3.2.1 Information provided to Europol
6	3.2.2 Information provided to the EMCDDA
7	3.3 Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance (Article 5.2(c) of the Council Decision)
7	3.4 A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the Council Decision
7	3.4.1 Health risks
7	3.4.2 Serious adverse events
8	3.4.3 Characteristics of users
8	3.4.4 Social risks
8	3.5 Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system (Article 5.2(e) of the Council Decision)
8	3.6 The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)
9	3.7 Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State (Article 5.2(g) of the Council Decision)
9	3.8 Further information (Article 5.2(h) of the Council Decision)
9	3.8.1 The chemical precursors that are known to have been used for the manufacture of the substance
10	3.8.2 The mode and scope of the established or expected use of the new substance
10	3.8.3 Other use of the new psychoactive substance and the extent of such use, the risks associated with this use of the new psychoactive substance, including the health and social risks
10	4. Information from the EMA (Article 5.3 of the Council Decision)
11	5. Conclusion
12	References

Acknowledgements

The EMCDDA would like to thank the following for their contribution in producing this publication:

- the Early Warning System (EWS) correspondents of the Reitox national focal points (NFPs) and experts from their national EWS networks;
- the Europol National Units (ENUs) and Europol Project Synergy;
- the national competent authorities responsible for human and veterinary medicinal products in the Member States, Norway and Iceland;
- the European Medicines Agency (EMA) and the European Commission;
- the World Health Organization;
- István Ujváry, hon. associate professor, Budapest University of Technology and Economics; hon. associate professor, University of Szeged; iKem BT, Budapest.

Project team: Anabela Almeida, Rachel Christie, Helgi Valur Danielsson, Michael Evans-Brown, Ana Gallegos, Rita Jorge, Roumen Sedefov (EMCDDA) and Werner Verbruggen (Europol).

1. Introduction

Article 5.1 of Council Decision 2005/387/JHA ⁽¹⁾ (hereinafter the 'Council Decision') stipulates that 'Where Europol and the EMCDDA, or the Council, acting by a majority of its members, consider that the information provided by the Member State on a new psychoactive substance merits the collection of further information, this information shall be collated and presented by Europol and the EMCDDA in the form of a Joint Report.' The Joint Report shall be submitted to the Council of the European Union, the European Medicines Agency (EMA) and the European Commission.

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance *N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl) isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint assessment based upon the following criteria:

1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and
6. evidence of cases of serious intoxication or fatalities.

The EMCDDA and Europol agreed that the information collected on 4-fluoroisobutyrylfentanyl satisfied criteria 4 and 6. The two agencies therefore concluded that sufficient information had been accumulated to merit the production of a Joint Report on 4-fluoroisobutyrylfentanyl as stipulated by Article 5.1 of the Council Decision.

2. Information collection process

In compliance with the provisions of the Council Decision, on 25 April 2017 the EMCDDA and Europol launched a procedure for the collection of information on 4-fluoroisobutyrylfentanyl, in order to prepare the Joint Report. The information was collected mainly through the Reitox national focal points in the Member States, Turkey and Norway as well as the Europol National Units. In addition, the EMA collected information through the national competent authorities responsible for human and veterinary medicinal products in the Member States as well as in Norway, Iceland and Liechtenstein. The EMA also provided information as relevant to the centralised procedure for authorising medicinal products. The information collection process was largely concluded by 6 June 2017.

Information collected by Europol

Europol asked the Europol National Units to provide information on:

- the level of production of 4-fluoroisobutyrylfentanyl in their country;
- the level of distribution of 4-fluoroisobutyrylfentanyl in their country;
- the level of trafficking of 4-fluoroisobutyrylfentanyl in their country, both for internal, transit or export purposes;
- the number of seizures of 4-fluoroisobutyrylfentanyl in their country, the total amount of the seizures, country of origin, details on the physical forms (including photos);
- the role of organised crime or criminal groups, in the production, distribution and trafficking of 4-fluoroisobutyrylfentanyl in their country; and
- any known aspect of violence and/or money laundering relating to the production and trafficking of 4-fluoroisobutyrylfentanyl.

Europol received responses from 16 Member States ⁽²⁾.

Information collected by the EMA

According to Article 5.3 of the Council Decision, the EMA requested that the national competent authorities responsible for human and veterinary medicinal products in the Member States, Norway, Iceland and Liechtenstein, provide information on whether:

- the new psychoactive substance 4-fluoroisobutyrylfentanyl has obtained a marketing authorisation;
- the new psychoactive substance 4-fluoroisobutyrylfentanyl is the subject of an application for a marketing authorisation;
- a marketing authorisation that had been granted in respect of the new psychoactive substance 4-fluoroisobutyrylfentanyl has been suspended.

Twenty-three countries provided a response to the EMA's request regarding human and/or veterinary medicinal products ⁽³⁾. The EMA also provided information as relevant to the centralised procedure for authorising human and veterinary medicinal products.

⁽²⁾ In alphabetical order: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, Slovakia, Slovenia and Spain.

⁽³⁾ Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, Norway, Poland, Spain, Sweden and the United Kingdom provided a response in relation to human and veterinary medicinal products. Croatia, Czech Republic, Hungary, Italy and the Netherlands provided a response in relation to human medicinal products. France, Portugal, Slovakia and Slovenia provided a response in relation to veterinary medicinal products.

⁽¹⁾ OJ L 127, 20.5.2005, p. 32.

Furthermore, in anticipation of Article 7.3 of the Council Decision in relation to the manufacturing of medicinal products in the European Union, the EMA also requested information on whether the new psychoactive substance 4-fluoroisobutyrylfentanyl is used to manufacture a medicinal product:

- which has been granted a marketing authorisation;
- for which an application has been made for a marketing authorisation;
- for which a marketing authorisation has been suspended by a competent authority.

Twenty-three countries ⁽⁴⁾ provided a response to the EMA's request in this regard. The EMA also provided information as relevant to the centralised procedure for authorising human and veterinary medicinal products.

Information collected by the EMCDDA

The EMCDDA collected information through:

- a structured questionnaire to the Reitox national focal points. The EMCDDA received replies from 27 Member States ⁽⁵⁾, as well as Turkey and Norway;
- reports previously provided to the European Union Early Warning System, including EMCDDA–Europol Reporting Forms and Progress Reports and Final Reports;
- routine monitoring of open source information;
- a specific information request to the World Health Organization on whether or not 4-fluoroisobutyrylfentanyl is under assessment by the United Nations system;
- a search of open source information conducted specifically for the production of the Joint Report which included: scientific and medical literature, official reports, grey literature, internet drug discussion forums and related websites (hereafter, 'user websites') and, online vendors selling 4-fluoroisobutyrylfentanyl.

Thus, the information included in sections 3.2.1 and 3.3 of the Joint Report was provided by Europol, while the EMCDDA provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information included in section 3.8.3 (in part) and section 4 was provided by the EMA.

3. Information required by Article 5.2 of the Council Decision

The order and titles of subsections 3.1 to 3.8 and section 4, below, are as they appear in Article 5.2(a) to (h) and Article 5.3(a) to (c) of the Council Decision; sections are cross-referenced with those set down in the Council Decision.

3.1 Chemical and physical description, including the names under which the new psychoactive substance is known (Article 5.2(a) of the Council Decision)

Chemical description and names

4-Fluoroisobutyrylfentanyl (4F-iBF) belongs to the 4-anilidopiperidine class of synthetic opioids. This class also includes fentanyl ⁽⁶⁾, which is internationally controlled and a number of other fentanils.

A total of fifteen fentanils are controlled under the United Nations Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol ⁽⁷⁾.

4-Fluoroisobutyrylfentanyl differs from fentanyl due to the presence of a fluorine atom on the anilido phenyl ring and also due to the presence of an isobutyramide group in place of the propanamide group present in fentanyl.

4-Fluoroisobutyrylfentanyl is the positional *iso* isomer of 4-fluoro-butyrylfentanyl (4F-BF) and thus both substances are structurally very closely related and they have the same molecular formula and molecular mass.

The molecular structure, molecular formula and molecular mass of 4-fluoroisobutyrylfentanyl are provided in in Figure 1.

⁽⁴⁾ Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, Norway, Poland, Spain, Sweden and the United Kingdom provided a response in relation to human and veterinary medicinal products. Croatia, Czech Republic, Hungary, Italy and the Netherlands provided a response in relation to human medicinal products. France, Portugal, Slovakia and Slovenia provided a response in relation to veterinary medicinal products.


⁽⁵⁾ A reply was not received from Slovakia.

⁽⁶⁾ *N*-phenyl-*N*-[1-(2-phenylethyl)piperidin-4-yl]acetamide.

⁽⁷⁾ 3-Methylfentanyl, 3-methylthiofentanyl, acetyl- α -methylfentanyl, α -methylfentanyl, α -methylthiofentanyl, β -hydroxy-3-methylfentanyl, β -hydroxyfentanyl, para-fluorofentanyl, thiofentanyl, acetylfentanyl and butyrylfentanyl are controlled under Schedule I and IV; alfentanil, fentanyl, sufentanil and remifentanil are controlled under Schedule I.

FIGURE 1

Molecular structure, molecular formula and molecular mass of 4-fluoroisobutyrylfentanyl. Information on 4-fluoro-butyrfentanyl and fentanyl is provided for comparison.



	4-fluoroisobutyrylfentanyl	4-fluoro-butyrfentanyl	fentanyl
Molecular formula	C ₂₃ H ₂₉ FN ₂ O	C ₂₃ H ₂₉ FN ₂ O	C ₂₂ H ₂₈ N ₂ O
Molecular mass	368.50	368.50	336.48

The synthesis of 4-fluoroisobutyrylfentanyl was first described in a study which included 23 other fentanyl-related compounds (Ohta *et al.*, 1999).

Commonly used names:

4-fluoroisobutyrylfentanyl or 4F-iBF

Systematic (IUPAC) name:

N-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl) isobutyramide

Other chemical names:

N-(4-fluorophenyl)-2-methyl-*N*-[1-(2-phenylethyl)piperidin-4-yl]propanamide;
N-(4-fluorophenyl)-2-methyl-*N*-[1-(2-phenylethyl)-4-piperidinyl]propanamide;
N-(4-fluorophenyl)-2-methyl-*N*-[1-(2-phenylethyl)-4-piperidyl]propanamide;
N-(4-Fluorophenyl)-*N*-(1-phenethyl-4-piperidinyl) isobutyramide;
N-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl) isobutyramide;
N-[1-(2-phenylethyl)piperidin-4-yl]-*N*-(4-fluorophenyl)-2-methylpropanamid (Swedish)

Other names and code names:

4-fluoro-isobutyrylfentanyl, 4-fluoro-isobutyrfentanyl, 4-fluoro-isobutyrylfentanyl, 4-F-iBF, 4-FiBF, 4-FiBF, FIBF, *p*-FIBF, *p*-FiBF

Chemical Abstracts Service (CAS) registry numbers ⁽⁸⁾:
 244195-32-2

IUPAC International Chemical Identifier Key (InChI Key) ⁽⁹⁾:
 OZDOSQNUJIXEOR-UHFFFAOYSA-N

The REACH registered substances database hosted by the European Chemicals Agency (ECHA) was searched using the CAS registry numbers listed above. The searches returned no hits.

Physical description

4-Fluoroisobutyrylfentanyl contains one basic nitrogen atom in the piperidine ring which can readily form salts with organic or inorganic acids.

There is no solubility data on 4-fluoroisobutyrylfentanyl or its hydrochloride salt, due to its similarity to fentanyl, the free base could be expected to be sparingly soluble in water; the hydrochloride and citrate salt could be expected to have greater aqueous solubility.

4-Fluoroisobutyrylfentanyl is expected to be lipophilic.

4-Fluoroisobutyrylfentanyl has been typically seized as a powder, in tablet form and as a liquid. A more detailed description of seizures and collected samples can be found in section 3.2.1 and section 3.2.2.

Detection and analysis

Methods documented in the literature for the detection of 4-fluoroisobutyrylfentanyl and/or its metabolites include: liquid chromatography high-resolution mass spectrometry (LC-HRMS) (Watanabe *et al.*, 2017; Helander *et al.*, 2017);

⁽⁸⁾ The Chemical Abstract Service Registry Number (CAS RN) is a unique numeric identifier assigned by the Chemical Abstract Service Division of the American Chemical Society to a specific, single chemical substance.

⁽⁹⁾ InChI Key is a unique, non-proprietary structural identifier of chemical substances useful in electronic sources.

high performance liquid chromatography time-of-flight (HPLC-TOF) (Watanabe *et al.*, 2017); gas chromatography–mass spectrometry (GC-MS), HPLC-TOF, Fourier transform infrared spectroscopy attenuated total reflectance (FTIR-ATR), gas chromatography–mass spectrometry–infrared (GC-MS-IR) condensed phase and nuclear magnetic resonance spectrometry (NMR) (Slovenian National Forensic Laboratory, 2016).

Chromatographic and spectrometric discrimination by thin-layer chromatography (TLC), gas chromatography (GC), GC-MS and FTIR for a number of fentanils are discussed by Ohta *et al.* (Ohta *et al.*, 1999).

It is important to note that GC-MS analysis of 4-fluoroisobutyrylfentanyl (4F-iBF) and 4-fluoro-butyrfentanyl (4F-BF) display very similar mass spectrometry fragmentation patterns. The ability to distinguish between both isomers requires the use of analytical reference standards or access to reference spectra for both substances.

It is possible that commonly used screening methods for fentanyl (i.e., ELISA) may not distinguish between 4-fluoroisobutyrylfentanyl and fentanyl due to the structural similarity between the two substances (US DEA, 2017). Identification of 4-fluoroisobutyrylfentanyl might therefore require further confirmatory analysis, such as mass spectrometry (US DEA, 2017). Similarly, 4-fluoroisobutyrylfentanyl is not expected to give a positive response to tests developed for morphine-type opioids. There is no information on the reaction of 4-fluoroisobutyrylfentanyl to presumptive colour tests.

3.2 Information on the frequency, circumstances and/or quantities in which a new psychoactive substance is encountered, and information on the means and methods of manufacture of the new psychoactive substance (Article 5.2(b) of the Council Decision)

The data reported to Europol discussed in section 3.2.1 may overlap with the data reported to the EMCDDA discussed in section 3.2.2.

3.2.1 Information provided to Europol

Europol received replies from 16 Member States (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, Slovakia, Slovenia and Spain).

Thirteen countries reported that they have no available information on 4-fluoroisobutyrylfentanyl (Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, Greece, Latvia, Lithuania, Luxembourg, Romania, Slovakia and Spain).

Three countries provided information on 4-fluoroisobutyrylfentanyl (Belgium, Germany and Slovenia). Slovenia provided information on a collected sample (section 3.2.2).

The level of production

No information was received in relation to the production of 4-fluoroisobutyrylfentanyl.

The level of distribution

Two small seizures in powder form, of 6 g each, were reported by Belgium and Germany.

The level of trafficking

No information was received in relation to the trafficking of 4-fluoroisobutyrylfentanyl.

3.2.2 Information provided to the EMCDDA

The EMCDDA received responses from 27 Member States ⁽⁵⁾, as well as from Turkey and Norway. Of these, five Member States (Belgium, Germany, Slovenia, Sweden and the United Kingdom) reported detections of 4-fluoroisobutyrylfentanyl ^(10, 11).

It is important to note that detections of 4-fluoroisobutyrylfentanyl may be under-reported since the substance is not routinely screened for. Three Member States (Austria, Slovenia and Sweden) and Norway reported that 4-fluoroisobutyrylfentanyl is part of routine screening in some (but not all) laboratories.

Seizures

In total, 23 seizures of 4-fluoroisobutyrylfentanyl were reported to the EMCDDA by four Member States: Sweden (20 seizures), Belgium (1), Germany (1) and the United Kingdom (1). The seizures comprise both police and customs cases. A majority of the seizures took place in 2016, while the most recent events took place in 2017.

⁽¹⁰⁾ 'Detections' is an all-encompassing term and may include seizures and/or collected and/or biological samples that are analytically confirmed. Seizure means a substance available (seized) through law enforcement activities (police, customs, border guards, etc.). Collected samples are those that are actively collected by drug monitoring systems (such as test purchases) for monitoring and research purposes. Biological samples are those from human body fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.).

⁽¹¹⁾ Finland reported a seizure of 0.05 g of a powder which was reported as '2F-, 3F- or 4F-BF; 2F-, 3F- or 4F-iBF', as the exact isomer was not determined. This case is not discussed further in this report.

Seizures of 4-fluoroisobutyrylfentanyl included:

- 12 seizures of tablets, all reported by Sweden, amounting to a total of 6 727 tablets;
- 8 seizures of powders (Belgium, Germany, Sweden and the United Kingdom) amounting to a total of 272 g;
- 3 seizures of liquids, all reported by Sweden, amounting to a total of 208 mL.

The powder seizure reported by Germany also contained furanylfentanyl and the powder seizure from the United Kingdom also contained fluorofentanyl (no isomer specified) and furanylfentanyl. For the remaining seizures, there is no information on whether other substances were also detected. No quantitative information on purity was reported.

The final destination of the seizure made in Belgium was Germany.

Collected samples

One collected sample was reported by Slovenia, which consisted of 5 g of powder test-purchased from the internet from a site based in China. No other substances were detected in the sample.

Biological samples

Serious adverse events with confirmed exposure to 4-fluoroisobutyrylfentanyl from biological samples are discussed in section 3.4.2.

3.3 Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance (Article 5.2(c) of the Council Decision)

No information concerning the involvement of organised crime in the manufacture and/or trafficking of the 4-fluoroisobutyrylfentanyl was provided.

Money laundering aspects

No information was received on money laundering in connection with the production and/or trafficking of 4-fluoroisobutyrylfentanyl.

Violence in connection with production, wholesale and distribution

No information was received on incidents of violence in connection with the production, wholesale and/or trafficking of 4-fluoroisobutyrylfentanyl.

3.4 A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the Council Decision

3.4.1 Health risks

Pharmacology and toxicology

Limited data suggests that 4-fluoroisobutyrylfentanyl is a μ -opioid receptor agonist that shares some similarities with opioid analgesics such as morphine and fentanyl (US DEA, 2017).

The acute effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, bradycardia, hypothermia and respiratory depression. They also have an abuse liability and dependence potential (Herz, 1993; Kieffer, 1999, Pasternak and Pan, 2013; Pattinson, 2008; Romberg *et al.*, 2003).

Similar to other opioid analgesics, the most serious acute health risk from using 4-fluoroisobutyrylfentanyl is probably respiratory depression, which in overdose could lead to apnoea, respiratory arrest and death (EMCDDA, 2017b; Pattinson, 2008; White and Irvine, 1999). This risk may be greater due to: the difficulty in diluting the substance; a lack of experience with its effects and dosing; the use of other central nervous system depressants at the same time (such as other opioids, benzodiazepines, gabapentanoids and alcohol); a lack of tolerance to opioids; and, using the substance alone (such as at home) which would make it more difficult for users to call for help in the case of poisoning.

The antidote naloxone should reverse acute poisoning caused by 4-fluoroisobutyrylfentanyl (Kim and Nelson, 2015; Ujváry *et al.*, 2017). Recent clinical and community experience in treating poisonings caused by fentanils suggests that larger than normal doses and repeated doses of naloxone may be required to fully reverse poisoning in some cases (EMCDDA, 2017b).

While there is limited data for 4-fluoroisobutyrylfentanyl, the chronic health risks might share some similarities to opioids such as heroin and other fentanils. This may include dependence.

3.4.2 Serious adverse events

Acute intoxications reported to the EMCDDA

No acute intoxication with confirmed exposure to 4-fluoroisobutyrylfentanyl were reported ⁽¹²⁾.

⁽¹²⁾ Sweden reported two acute intoxications with suspected exposure to 4-fluoroisobutyrylfentanyl. These cases are not discussed further in this report.

Deaths reported to the EMCDDA

In total, 16 deaths with confirmed exposure to 4-fluoroisobutyrylfentanyl were reported by Sweden ^(13, 14). The cases occurred between 2016 and 2017.

Of the deaths, 14 were male (88 %) and two were female (12 %). The males were aged between 24 and 52 years (mean 36, median 36); the females were aged 24 and 36 years. A range of other substances were detected in the deaths, including other central nervous system depressants. Other opioids were only detected in five cases. Where known, many of the individuals were found dead in a home environment. In at least 11 cases, 4-fluoroisobutyrylfentanyl was the cause of death or contributed to the death.

3.4.3 Characteristics of users

Similar to other new fentanils, 4-fluoroisobutyrylfentanyl is sold and used as a 'legal' substitute for illicit opioids and prescription opioids; this may include for self-medication, such as the alleviation of pain and/or opioid withdrawal. Users may include high-risk drug users as well as others (such as psychonauts) who may be experimenting with the substance.

3.4.4 Social risks

While there is limited data for 4-fluoroisobutyrylfentanyl, the social risks might share some similarities with opioids such as heroin and other fentanils.

Of additional note is that, in the past few years, fentanils have been sold in Europe as ready-to-use nasal sprays and e-liquids for vaping. In general, these novel products could make it easier to use such substances (with similar effects to injecting) and make them more socially acceptable.

Similar to other fentanils, accidental exposure to 4-fluoroisobutyrylfentanyl may also pose a risk of severe poisoning. Those at risk may include the family and friends of users, law enforcement, emergency personnel, medical and forensic laboratory personnel, as well as those working in the postal services. Where required, these risks should be assessed and appropriate procedures, training and protective measures should be implemented. This may include training in resuscitation and adequate provision of the antidote naloxone.

⁽¹³⁾ One of the deaths had been previously included in the recent Joint Report and risk assessment of acryloylfentanyl (EMCDDA, 2016 and 2017a).

⁽¹⁴⁾ The United Kingdom reported a total of four deaths in which confirmation of 4-fluoroisobutyrylfentanyl is currently pending. These cases are not discussed further in this report.

3.5 Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system (Article 5.2(e) of the Council Decision)

The World Health Organization is the specialised United Nations agency designated for the evaluation of the medical, scientific and public health aspects of psychoactive substances under the Single Convention on Narcotic Drugs, 1961 and the Convention on Psychotropic Substances, 1971.

On 1 May 2017, the World Health Organization informed the EMCDDA that 4-fluoroisobutyrylfentanyl is currently not under assessment and has not been under assessment by the UN system.

Since then, the World Health Organization has published a list of substances that will be reviewed at the 39th meeting of the WHO Expert Committee on Drug Dependence (ECDD) that will be held in November 2017. 4-Fluoroisobutyrylfentanyl was included in the list of substances that will be reviewed. At the time of writing this report neither a critical review nor a written recommendation had been published.

3.6 The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)

The first official EMCDDA–Europol notification of 4-fluoroisobutyrylfentanyl dates from 26 August 2016 from the Slovenian national focal point. The Reporting Form details the identification of 4-fluoroisobutyrylfentanyl in 5 g of white powder in a collected sample which was test-purchased by the Slovenian National Forensic Laboratory as part of the EU co-funded project RESPONSE, on 25 May 2016 in Ljubljana. The sample was shipped from China. The substance was analytically confirmed by GC-MS, HPLC-TOF, FTIR-ATR, GC-MS-IR (condensed phase), ion chromatography and NMR by the Slovenian National Forensic Laboratory and the Faculty of Chemistry and Chemical technology of the University of Ljubljana.

4-Fluoroisobutyrylfentanyl was added to the list of new psychoactive substances monitored by the EMCDDA and Europol through the European Union Early Warning System. A profile of the substance was created on the European Database on New Drugs (EDND). Since then, analytical details and other information, including a public health alert, have been exchanged between the EMCDDA, Europol and the Member States, Turkey and Norway, on an ad hoc basis; the European Commission and the EMA have been kept duly informed.

It is important to note that 4-fluoroisobutyrylfentanyl was first identified in a seizure in Germany in November 2016.

4-Fluoroisobutyrylfentanyl was identified in 6.176 g of white powder by German Police in Berlin. Of note was that the powder was also found to contain furanylfentanyl.

3.7 Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State (Article 5.2(g) of the Council Decision)

Six Member States (Cyprus, Estonia, Latvia, Lithuania, Sweden and the United Kingdom) reported that 4-fluoroisobutyrylfentanyl is controlled under drug control legislation.

Two Member States (Austria and Poland) reported that 4-fluoroisobutyrylfentanyl is controlled under specific new psychoactive substances control legislation.

Nineteen Member States (Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia and Spain) and Turkey reported that 4-fluoroisobutyrylfentanyl is not subject to control measures at the national level.

Norway reported that it is not known whether 4-fluoroisobutyrylfentanyl is controlled, as the substance is not covered by any of the generic groups defined in the drug control legislation. It may be covered by the medicinal products legislation if its effects are proved by scientific evidence.

Slovakia did not provide information on the control status of 4-fluoroisobutyrylfentanyl.

3.8 Further information (Article 5.2(h) of the Council Decision)

3.8.1 The chemical precursors that are known to have been used for the manufacture of the substance

No information was reported by the Member States, Turkey or Norway, about the chemical precursors or manufacturing methods used to make the 4-fluoroisobutyrylfentanyl which has been detected within Europe.

The synthesis of 4-fluoroisobutyrylfentanyl was first described in 1999 (Ohta *et al.*, 1999). 4-Fluoroisobutyrylfentanyl and

23 other fentanyl-related compounds were synthesised by Van Bever *et al.* (Van Bever *et al.*, 1974).

The manufacture of 4-fluoroisobutyrylfentanyl relies on precursors and synthetic methods similar to those used for the manufacture of pharmaceutical fentanyl (Casy and Huckstep, 1988; Gupta *et al.*, 2013; Zee and Wang, 1980). Therefore the methods developed for the synthesis of fentanyl are applicable to the synthesis of 4-fluoroisobutyrylfentanyl. Use of a different acylating agent in the final acylation step, such as isobutyryl chloride would produce 4-fluoroisobutyrylfentanyl. A one-step method uses *N*-phenyl-1-(2-phenylethyl)piperidin-4-amine (4-ANPP) and isobutyryl chloride for the manufacture of the substance.

Two potential precursors of fentanyl and other fentanils 4-ANPP as well as *N*-phenethyl-4-piperidone (NPP), a pre-precursor have been recently scheduled under the United Nations Convention against Traffic in Narcotic Drugs and Psychotropic Substances, 1988 ⁽¹⁵⁾.

Most of the synthetic procedures are straightforward, use common laboratory equipment and precursors and detailed recipes are available on the internet ⁽¹⁶⁾. While only basic knowledge of synthetic chemistry is required, due to the potency of fentanils extreme caution is required when carrying out the final synthetic step as well as when purifying and handling the substance ⁽¹⁷⁾. Exposure of the skin and mucous membranes to fentanils as well as their inhalation pose a serious risk of accidental poisoning. In addition to exercising extreme caution, suitable personal protective equipment as well as sufficient stocks of naloxone as an antidote to poisoning following accidental exposure should be available when handling materials suspected to contain these substances (CDCP, 2013; US DEA, 2016).

In summary, the synthesis of 4-fluoroisobutyrylfentanyl has been described in the literature. Other routes developed for the production of fentanyl may also be used for the manufacture of 4-fluoroisobutyrylfentanyl. There is no information on the actual method(s) used for the production of 4-fluoroisobutyrylfentanyl that has been detected in Europe to date.

⁽¹⁵⁾ Table I of the United Nations Convention against Traffic in Narcotic Drugs and Psychotropic Substances, 1988.

⁽¹⁶⁾ The detailed description of the most common procedure, referred to as the 'Siegfried method', is readily available on the internet (see, for example, <http://opioids.com/fentanyl/synthesis.html>).

⁽¹⁷⁾ Self-educated clandestine chemists commented on the risk while discussing the synthesis of fentanyl and its potent 3-methyl and α -methyl homologues (comment was posted on 7 May, 2002); available at: <https://the-hive.archive.erozid.org/forum/showflat.pl?Cat=&Number=260275> (Accessed: 27 June 2017).

3.8.2 The mode and scope of the established or expected use of the new substance

No studies were identified that have examined the mode and scope of established or expected use of 4-fluoroisobutyrylfentanyl. Given the limited information currently available, the relevant information has been included in the previous sections.

3.8.3 Other use of the new psychoactive substance and the extent of such use, the risks associated with this use of the new psychoactive substance, including the health and social risks

No information was provided by the Member States, Turkey or Norway that indicated that 4-fluoroisobutyrylfentanyl had any other use apart from in analytical reference materials and scientific research.

From the available information, it does not appear that 4-fluoroisobutyrylfentanyl is used in the manufacture of a medicinal product in the European Union. However, the data collection is incomplete and some countries indicated that this information is not known. It is understood that the collection of such information is a challenge in the absence of a database on the synthetic route of all medicinal products.

Ten countries (Austria, Belgium, Croatia, Denmark, Greece, Italy, the Netherlands, Poland, Spain and the United Kingdom) reported that 4-fluoroisobutyrylfentanyl is not used to manufacture a medicinal product for human use. Nine countries (Czech Republic, Estonia, Finland, Germany, Hungary, Ireland, Latvia, Norway and Sweden) reported that it was unknown if 4-fluoroisobutyrylfentanyl is used to manufacture a medicinal product for human use.

In addition, the EMA reported that it is not known if 4-fluoroisobutyrylfentanyl is used in the manufacture of medicinal products for human use and which are centrally authorised within the European Union.

Ten countries (Austria, Belgium, Denmark, France, Greece, Latvia, Poland, Slovakia, Spain and the United Kingdom) provided information that 4-fluoroisobutyrylfentanyl is not used to manufacture a medicinal product for veterinary use. Eight countries (Estonia, Finland, Germany, Ireland, Norway, Portugal, Slovenia and Sweden) reported that it was unknown if 4-fluoroisobutyrylfentanyl is used to manufacture a medicinal product for veterinary use.

In addition, the EMA reported that it is not known if 4-fluoroisobutyrylfentanyl is used in the manufacture of medicinal products for veterinary use and which are centrally authorised within the European Union.

4. Information from the EMA (Article 5.3 of the Council Decision)

Nineteen countries (Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Italy, Latvia, the Netherlands, Norway, Poland, Spain, Sweden and the United Kingdom) reported that:

- 4-fluoroisobutyrylfentanyl has not been granted a marketing authorisation as a medicinal product for human use;
- 4-fluoroisobutyrylfentanyl is not the subject of an application for a marketing authorisation as a medicinal product for human use;
- there had been no cases of suspended marketing authorisation in respect to 4-fluoroisobutyrylfentanyl as a human medicine.

Eighteen countries (Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Latvia, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the United Kingdom) reported that:

- 4-fluoroisobutyrylfentanyl has not been granted a marketing authorisation as a medicinal product for veterinary use;
- 4-fluoroisobutyrylfentanyl is not the subject of an application for a marketing authorisation as a medicinal product for veterinary use;
- there had been no cases of suspended marketing authorisation in respect to 4-fluoroisobutyrylfentanyl as a veterinary medicine.

The EMA also reported that 4-fluoroisobutyrylfentanyl:

- has not been granted a marketing authorisation as a medicinal product for neither human nor veterinary use through the centralised procedure;
- is not the subject of an application for a marketing authorisation for neither human nor veterinary use through the centralised procedure;
- is not the subject of a suspended marketing authorisation for neither human nor veterinary use through the centralised procedure.

5. Conclusion

4-Fluoroisobutyrylfentanyl belongs to a group of synthetic opioids known as the fentanils. It is closely related to fentanyl, which is controlled under the United Nations Single Convention on Narcotic Drugs, 1961. Data suggests that 4-fluoroisobutyrylfentanyl may be an opioid narcotic analgesic in humans and, as such, may have an abuse liability and dependence potential; overall, these effects may be broadly comparable to fentanyl. The most serious acute health risk posed by 4-fluoroisobutyrylfentanyl is likely to be respiratory depression, which in overdose is life-threatening. The antidote naloxone should reverse acute poisoning.

4-Fluoroisobutyrylfentanyl has been available in the European Union since at least July 2016. It has been detected in four Member States where it has been seized as a powder, tablets and liquids. The detected quantities are relatively small; however, they should be seen within the context of the high potency that is typical of the fentanils.

There are indications that the 4-fluoroisobutyrylfentanyl currently available on the market is synthesised by chemical companies based in China. 4-Fluoroisobutyrylfentanyl is sold online often under the guise of a 'research chemical'. It is available in wholesale amounts and in consumer amounts.

Sixteen deaths with confirmed exposure to 4-fluoroisobutyrylfentanyl have been reported by one Member State. In at least 11 of the deaths, 4-fluoroisobutyrylfentanyl was the cause of death or contributed to the death.

4-Fluoroisobutyrylfentanyl is sold and used as a substitute for illicit opioids and prescription opioids. Similar to other fentanils, serious concerns exist that the substance could be supplied surreptitiously to a range of drug users.

4-Fluoroisobutyrylfentanyl is under assessment within the United Nations system. It will be reviewed at the 39th meeting of the WHO Expert Committee on Drug Dependence (ECDD) that will be held in November 2017. Currently, neither a critical review nor a written recommendation has been published. 4-Fluoroisobutyrylfentanyl is not subject to control measures in 19 Member States and Turkey.

We conclude that the health and social risks caused by the manufacture, trafficking and use of 4-fluoroisobutyrylfentanyl and the involvement of organised crime and possible consequences of control measures, could be thoroughly assessed through a risk assessment procedure in accordance with Article 6 of Council Decision 2005/387/JHA.

The EMCDDA and Europol will continue to intensively monitor 4-fluoroisobutyrylfentanyl in order to ensure that new information is provided to the Member States, the EMA and the Commission via the information exchange of the European Union Early Warning System.

References

- Casy, A. F., Huckstep, M. R., (1988), 'Structure-activity studies of fentanyl', *Journal of Pharmacy and Pharmacology*, 40(9), pp. 605–8. Available at: <https://doi.org/10.1111/j.2042-7158.1988.tb05318.x>
- CDCP (2013), *Recommendations for laboratory testing for acetyl fentanyl and patient evaluation and treatment for overdose with synthetic opioid*, Centers for Disease Control and Prevention, Available at: <http://emergency.cdc.gov/han/han00350.asp>
- EMCDDA (2016), *EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl)*, Publications Office of the European Union, Luxembourg. Available at: <http://emcdda.europa.eu/publications/joint-reports/acryloylfentanyl>
- EMCDDA (2017a), *Risk assessment report on a new psychoactive substance: N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl)*, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. Available at: www.emcdda.europa.eu/attachements.cfm/att_256126_EN_Risk%20assessment%20report%20acryloylfentanyl%20with%20annexes%20and%20cover.pdf
- EMCDDA (2017b), *Risk assessment report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanlylfentanyl)*, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. Available at: www.emcdda.europa.eu/attachements.cfm/att_256125_EN_Risk%20assessment%20report%20furanlylfentanyl%20with%20annexes%20and%20cover.pdf
- Gupta, P. K., Yadav, S. K., Bhutia, Y. D., Singh, P., Rao, P., Gujar, N. L., Ganesan, K., Bhattacharya, R., (2013), 'Synthesis and comparative bioefficacy of N-(1-phenethyl-4-piperidinyl)propionanilide (fentanyl) and its 1-substituted analogs in Swiss albino mice', *Medicinal Chemistry Research* 22(8), pp. 3888–96. Available at: <https://doi.org/10.1007/s00044-012-0390-6>
- Helander, A., Bäckberg, M., Signell, P., Beck, O., (2017), 'Intoxications involving acrylfentanyl and other novel designer fentanyls – results from the Swedish STRIDA project', *Clinical Toxicology* 55(6), pp. 589–99. Available at: <http://doi.org/10.1080/15563650.2017.1303141>
- Herz, A. (ed.), (1993), *Opioids II*, Springer-Verlag, Berlin.
- Kieffer, B. L., (1999), 'Opioids: first lessons from knockout mice', *Trends in Pharmacological Sciences*, 20, 19–26. Available at: [https://doi.org/10.1016/S0165-6147\(98\)01279-6](https://doi.org/10.1016/S0165-6147(98)01279-6)
- Kim, H. K., Nelson, L. S., (2015), 'Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review', *Expert Opinion on Drug Safety*, 14(7), 1137–46. Available at: <https://doi.org/10.1517/14740338.2015.1037274>
- Ohta, H., Suzuki, S., Ogasawara, K., (1999), 'Studies on Fentanyl and Related Compounds IV. Chromatographic and Spectrometric Discrimination of Fentanyl and its Derivatives', *Journal of Analytical Toxicology* 23(4), pp. 280–5. Available at: <https://doi.org/10.1093/jat/23.4.280>
- Pasternak, G. W., Pan, Y. X., (2013), 'Mu opioids and their receptors: evolution of a concept', *Pharmacological Reviews*, 65(4), pp. 1257–317. Available at: <https://doi.org/10.1124/pr.112.007138>
- Pattinson, K. T., (2008), 'Opioids and the control of respiration', *British Journal of Anaesthesia*, 100(6), pp. 747–58. Available at: <https://doi.org/10.1093/bja/aen094>
- Romberg, R., Sarton, E., Teppema, L., Matthes, H. W. D., Kieffer, B. L., Dahan, A., (2003), 'Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and I-opioid receptor deficient mice', *British Journal of Anaesthesia*, 91, pp. 862–70. Available at: <https://doi.org/10.1093/bja/aeg279>
- Ohta, H., Suzuki, S., Ogasawara, K. (1999), 'Studies on Fentanyl and Related Compounds IV. Chromatographic and Spectrometric Discrimination of Fentanyl and its Derivatives', *Journal of Analytical Toxicology*, 23, pp. 280–5. Available at: <https://doi.org/10.1093/jat/23.4.280>

- | Slovenian National Forensic Laboratory (2016), Analytical report 4F-iBF (C23H29FN2O) *N*-(4-fluorophenyl)-2-methyl-*N*-[1-(2-phenylethyl)piperidin-4-yl]propanamide, NPS and related compounds – analytical reports. European project RESPONSE to challenges in forensic drugs analyses. Available at: http://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4F-iBF-ID-1573-16_rpt100816.pdf
- | Ujváry, I., Jorge, R., Christie, R., Le Ruez, T., Danielsson, H. V., Kronstrand, R., Elliott, S., Gallegos, A., Sedefov, R., Evans-Brown, M. (2017), 'Acryloylfentanyl, a recently emerged new psychoactive substance: a comprehensive review', *Forensic Toxicology*, 35, pp. 232–43. Available at: <https://doi.org/10.1007/s11419-017-0367-8>
- | US DEA (2016), News Release, DEA issues carfentanil warning to police and public. United States Drug Enforcement Administration. Available at: <https://www.dea.gov/divisions/hq/2016/hq092216.shtml>
- | US DEA (2017), 4-Fluoroisobutyryl fentanyl. Background information and evaluation of 'three factor analysis' (factors 4, 5 and 6) for temporary scheduling, United States Drug Enforcement Administration. Available at: <https://www.regulations.gov/contentStreamer?documentId=DEA-2017-0004-0002&contentType=pdf>
- | Van Bever, W. F. M., Niemegeers, C. J., Janssen, P. A., (1974), 'Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of *N*-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-*N*-phenylpropanamide and *N*-[3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl]-*N*-phenylpropanamide', *Journal of Medicinal Chemistry* 17(10), pp. 1047–51. Available at: <https://doi.org/10.1021/jm00256a003>
- | Watanabe, S., Vikingsson, S., Roman, M., Green, H., Kronstrand, R., Wohlfarth, A., (2017), 'In vitro and in vivo metabolite identification studies for the new synthetic opioids acetylfentanyl, acrylfentanyl, furanylfentanyl, and 4-fluoro-isobutyrylfentanyl', *The American Association of Pharmaceutical Scientists Journal* 19(4), pp. 1102–22. Available at: <https://doi.org/10.1208/s12248-017-0070-z>
- | White, J. M., Irvine, R. J., (1999), 'Mechanisms of fatal opioid overdose', *Addiction*, 94, pp. 961–72. Available at: <https://doi.org/10.1046/j.1360-0443.1999.9479612.x>
- | Zee, S.H., Wang, W.K., (1980), 'A new process for the synthesis of fentanyl', *Journal of the Chinese Chemical Society* 27(4), pp. 147–49.

Recommended citation:

European Monitoring Centre for Drugs and Drug Addiction (2017), *EMCDDA–Europol Joint Report on a new psychoactive substance: N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide (4-fluoroisobutyrylfentanyl; 4F-iBF)*, Joint Reports, Publications Office of the European Union, Luxembourg.

The Joint Report represents a legal document, prepared in cooperation with the Council, EMA, and Commission and is published in the original version that has not been edited.

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the central source and confirmed authority on drug-related issues in Europe. For over 20 years, it has been collecting, analysing and disseminating scientifically sound information on drugs and drug addiction and their consequences, providing its audiences with an evidence-based picture of the drug phenomenon at European level.

The EMCDDA's publications are a prime source of information for a wide range of audiences including: policymakers and their advisors; professionals and researchers working in the drugs field; and, more broadly, the media and general public. Based in Lisbon, the EMCDDA is one of the decentralised agencies of the European Union.

Related publications and websites

EMCDDA

| *European Drug Report 2017: Trends and developments, 2017*

EMCDDA and Europol

| *EMCDDA–Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA, Implementation reports, 2017*

These and all other EMCDDA publications are available from www.emcdda.europa.eu/publications

| EMCDDA Action on new drugs:
www.emcdda.europa.eu/drug-situation/new-drugs

Legal notice: The contents of this publication do not necessarily reflect the official opinions of the EMCDDA's partners, the EU Member States or any institution or agency of the European Union. More information on the European Union is available on the Internet (europa.eu).

Luxembourg: Publications Office of the European Union
Web: [doi:10.2810/033972](https://doi.org/10.2810/033972) | ISBN 978-92-9497-207-1

© European Monitoring Centre for Drugs and Drug Addiction, 2017
Reproduction is authorised provided the source is acknowledged.

This publication is only available in electronic format.
EMCDDA, Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal
Tel. (351) 211 21 02 00 | info@emcdda.europa.eu
emcdda.europa.eu | twitter.com/emcdda | facebook.com/emcdda

